Source comparison
Melanotan-2 for Skin Pigmentation: Research Applications Comparison
UV-Independent Pigmentation MC1R activation → tyrosinase upregulation → eumelanin synthesis 0.05–0.08 mg/kg SC every 48h × 10–14 days L* reduction 5–8 units; visible pigmentation onset 5–7 days Pigmentation fades over 4–8 weeks; requires repeated dosing cycles
This comparison does not assign a generated winner or score.
- UV-Independent Pigmentation
- MC1R activation → tyrosinase upregulation → eumelanin synthesis
- 0.05–0.08 mg/kg SC every 48h × 10–14 days
- L* reduction 5–8 units; visible pigmentation onset 5–7 days
- Pigmentation fades over 4–8 weeks; requires repeated dosing cycles
- Photoprotection (MED Increase)
- Melanin density increase → UV absorption in epidermis
- 0.16 mg/kg SC over 14 days
- MED increase 2.1–2.8 fold vs baseline
- Does not eliminate burn risk; systemic side effects at protective doses
- Vitiligo Repigmentation
- MC1R stimulation in depigmented patches
- 0.025 mg/kg SC 3× weekly × 12 weeks
- 30–40% repigmentation in 50% of subjects (small trials, n=12–18)
- High inter-individual variability; MC4R side effects limit dosing
- Erythropoietic Protoporphyria (EPP)
- Afamelanotide (Melanotan-1 analog) used; melanin ↑ → light tolerance ↑
- 16 mg implant every 60 days (afamelanotide)
- Pain-free sun exposure time increased 69% (SCENESSE trials)
- Melanotan-2 not used due to MC4R effects; afamelanotide FDA-approved for EPP only
- The photoprotection data is the most robust. MED increases of 2–3× are reproducible across multiple trials and correlate directly with melanin density measured via reflectance spectroscopy. The limitation is that achieving photoprotective melanin levels requires doses high enough to produce MC4R-mediated side effects (nausea, flushing, erectile effects) in 60–70% of subjects, which is why the peptide never reached FDA approval for tanning or photoprotection indications.